|The department of Nephrology from Ninth People’s Hospital fought over major obstacles with the development of multidisciplinary joint treatment|
The department of Nephrology from Shanghai Ninth People‘s Hospital affiliated to Shanghai Jiao Tong University School of Medicine has established a new severe chronic kidney diseases (CKD) laboratory, and it aims tol adopt a multidisciplinary joint treatment. With the new mode of university-industry cooperation, they will overcome difficulty, continuously introduce new achievements in the field of severe chronic kidney diseases, and strive to become a famous severe chronic kidney diseases research institution at home and abroad and one of the new product research and development platforms.
professor Ding Feng, director of the department of Nephrology from Shanghai Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine introduced about the blood purification technology. In his opinion, the use of anticoagulants is needed to keep the extracorporeal circulation smoothly, but the whole systemic anticoagulation can aggravate bleeding tendency, especially applicable to merge in patients at high risk of bleeding risk. So how to carry out this procedure? It requires local anticoagulation. Among them, the internationally recognized as the best technology is the local citrate anticoagulation method. Regional citrate anticoagulation as it is, however, there are a lot of problems,one of which is how much folic acid and calcium lost there is no ready-made material. And those are only available with a doctor‘s experience, while doctors are doing treatment for patients, monitoring, adjustment. And it refers to as the “trial and error method”, thus this approach greatly increased the economic burden of patients, and medical staff working strength, is unfavorable to the safety of this technology.
As one of the earliest of blood purification technology departments in Shanghai, after several years of efforts, The department of Nephrology from Shanghai Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine now has a regional citrate anticoagulation therapy parameter for the quantitative analysis, and it greatly simplifies the treatment difficulty, and improves the safety and effectiveness of the technology.
As a completely original scientific research achievement, The department of Nephrology from Shanghai Ninth People‘s Hospital affiliated to Shanghai Jiao Tong University School of Medicine is currently working with relevant local citrate anticoagulation equipment researches and development,and enterprises cooperation among universities. The prototype has been forming, and the next step will be mass production, which promotes to the medical units at all levels, in order to benefit more patients.
Critically ill patients tend to have more systems, multiple organ damages and dysfunction, so that the treatment often requires multidisciplinary collaborative operations. “However, interdisciplinary collaboration in our country is faced with many challenges.” professor Ding Feng said, with the development of more and more sophisticated science , many experts focus on a branch to make breakthrough, and it is critical to learn the development of kidney disease which needs not only knowledge of nephrology, but also needs to adopt the understanding of immunology, material science, mechanics, electrical engineering, and other experts in the field of cooperation, with the collaborative research achieved.
It is reported that the department of Nephrology from Shanghai Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine will study the new apprpach from three aspects: first, cooperation and basic subject, severe chronic kidney disease pathogenesis research; Second, through clinical patient cohort study, looking for a variety of severe kidney disease early diagnosis biomarkers, prognostic risk factors; And the third is the key technology innovation, including the optimization of existing treatment technology and research and development of new technology and new method.